Tag: PYC

Phylogica ASX PYC Therapeutics human retina in a dish model drug childhood blindness

Phylogica achieves milestone in drug study aimed at treating childhood blindness

Biotechnology company Phylogica (ASX: PYC) is one step closer to finding a treatment for the leading cause of childhood blindness, achieving a major milestone in its human ‘retina in a dish’ study. ...
Phylogica ASX PYC Therapeutics drug delivery animals Anti-Sense Oligonucleotide

Phylogica’s cell penetrating platform linked to effective administration of drugs for genetic eye disease

A drug delivery platform developed by biotechnology company Phylogica (ASX: PYC) has been shown to be the most effective method of administering anti-sense oligonucleotide (ASO) medications to patient...
Phylogica ASX PYC human cell penetrating peptide blinding eye disease

Phylogica’s cell peptide delivery platform achieves early success in human cell studies for blinding eye diseases

Perth-based biotech company Phylogica (ASX: PYC) has reported positive early stage results from a pilot study of human cells using its proprietary drug delivery technology to create a treatment for bl...
Phylogica ASX PYC study results Cell Penetrating Peptide CPP platform

Phylogica obtains successful time-course study results for flagship CPP platform

Biotechnology company Phylogica (ASX: PYC) has unveiled favourable lab results in relation to its time-course studies in animals, with superior performance to current benchmarks officially confirmed. ...
Phylogica ASX PYC peptide vaccine T-Cell expansion results in vivo

Phylogica reports positive peptide vaccine T-Cell expansion results in vivo

Perth-based biotechnology company Phylogica (ASX: PYC) has announced a successful round of in vivo results in the evaluation of its cell-penetrating peptide (CPP) vaccine program. Peptides are pote...
Phylogica ASX PYC Cre deliver drugs cells biotech biology

Purposeful cell targeting delivers commercial spoils for Phylogica

Biotech company Phylogica (ASX: PYC) has announced it has developed a new recombination enzyme, Cre, thereby supplementing its ongoing research into a proprietary in vitro drug delivery platform. P...
Phylogica ASX PYC peptide technology cancer vaccine

Phylogica’s peptide technology effective in development of cancer vaccine

Phylogica (ASX: PYC) has praised the effectiveness of its Functional Penetrating Peptide (FPP) technology to stimulate an immune response and extend cancer survival rates through recent testing on mic...